NCT06944067Recruiting
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
Observational Study to Determine Red Blood Cell Alloimmunization Risk Etiology in Patients With Sickle Cell Disease
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 24 Apr 2025
- Start date
- 24 Jun 2025
- Primary completion date
- 10 Apr 2030
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- Diseases
- Sickle cell disease
- NCT number
- NCT06944067
What you commit to
- Study type: Observational
- Planned participants: 50
- From 24 Jun 2025 to the primary completion date, 10 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking immunosuppressive medications at time of enrollment
Other illness
- History of transplant (e.g., organ, bone marrow, stem cell)
Other
- An individual who meets any the following criteria will be excluded from participation in this study:
- Impaired decision-making capability, with or without a legally authorized representative
- Confirmed pregnancy
Criteria the registry did not label
- INCLUSION CRITERIA
- To be eligible to participate in this study, an individual must meet all of the following criteria:
- 1\. Individual (\> 2 years of age) with confirmed SCD diagnosis who meets at least one of the following conditions:
- History of greater than ten administered transfusions or 20 transfusion units (where known)
- History of one or more antibody screens
- Known candidate variant genotype
Age in the registry: 2 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.